This document is a publication of a United States Patent and Trademark Office (USPTO) patent application, specifically application number US20260083703A1, filed on April 18, 2023. The application, titled 'INDOLINE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO,' describes novel indoline derivatives, their preparation, compositions containing them, and their use in activating serotonin receptors. The intended therapeutic applications include the treatment of psychosis, mental illnesses, and central nervous system (CNS) disorders.

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on regulated entities. However, it signals potential future developments in pharmaceutical research and development within the specified therapeutic areas. Companies involved in drug discovery and development, particularly those focusing on neurological and psychiatric disorders, should be aware of this application as it may indicate emerging intellectual property in the field.